Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Dermapharm Holding SE (DMP.DE)
Grünwald, DE
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.68% | +7.10% | +11.11% | +36.86% | +46.80% | +31.00% | +29.82% | +6.45% | -28.47% | +94.23% | +94.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.3% Q1'26: +1.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+16.6% ★ Q1'26: +35.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+14.8% Q1'26: +9.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+19.0% ★ Q1'26: +23.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.3% ★ Q1'26: +13.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.35× Q1'26: 2.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
467.12M
est: 467.22M (0.0%)
|
572.42M
est: 571.00M (+0.2%)
|
700.88M
est: 696.59M (+0.6%)
|
793.83M
est: 794.86M (-0.1%)
|
942.91M
est: 945.32M (-0.3%)
|
1.02B
est: 1.03B (-0.4%)
|
1.14B
est: 1.15B (-1.0%)
|
1.18B
est: 1.19B (-0.6%)
|
1.16B
est: 1.18B (-0.9%)
|
1.21B
1.19B – 1.23B
+3.2% YoY
|
1.26B
1.24B – 1.28B
+3.8% YoY
|
1.29B
1.29B – 1.29B
+2.5% YoY
|
1.35B
1.33B – 1.37B
+4.5% YoY
|
| EBITDA |
110.43M
est: 134.45M (-17.9%)
|
134.12M
est: 164.32M (-18.4%)
|
170.26M
est: 122.22M (+39.3%)
|
183.81M
est: 118.13M (+55.6%)
|
358.10M
est: 129.24M (+177.1%)
|
329.82M
est: 135.66M (+143.1%)
|
265.55M
est: 338.76M (-21.6%)
|
320.91M
est: 347.18M (-7.6%)
|
314.31M
est: 347.45M (-9.5%)
|
358.43M
352.98M – 364.13M
+3.2% YoY
|
371.95M
366.18M – 379.43M
+3.8% YoY
|
381.24M
380.30M – 382.18M
+2.5% YoY
|
398.48M
392.36M – 405.68M
+4.5% YoY
|
| EBIT |
95.21M
est: 98.16M (-3.0%)
|
110.01M
est: 119.96M (-8.3%)
|
120.14M
est: 129.01M (-6.9%)
|
134.65M
est: 140.14M (-3.9%)
|
301.81M
est: 153.32M (+96.8%)
|
228.64M
est: 160.94M (+42.1%)
|
160.97M
est: 245.67M (-34.5%)
|
230.41M
est: 251.77M (-8.5%)
|
221.75M
est: 251.97M (-12.0%)
|
259.93M
255.98M – 264.07M
+3.2% YoY
|
269.74M
265.55M – 275.16M
+3.8% YoY
|
276.47M
275.79M – 277.15M
+2.5% YoY
|
288.98M
284.54M – 294.20M
+4.5% YoY
|
| Net Income |
77.74M
est: 23.91M (+225.2%)
|
75.32M
est: 77.50M (-2.8%)
|
77.20M
est: 90.39M (-14.6%)
|
85.83M
est: 90.52M (-5.2%)
|
209.58M
est: 99.03M (+111.6%)
|
134.24M
est: 122.56M (+9.5%)
|
62.37M
est: 83.04M (-24.9%)
|
113.79M
est: 109.79M (+3.6%)
|
132.41M
est: 119.81M (+10.5%)
|
134.00M
123.80M – 139.75M
+11.8% YoY
|
155.12M
129.06M – 155.46M
+15.8% YoY
|
166.16M
139.75M – 175.56M
+7.1% YoY
|
183.21M
179.55M – 187.52M
+10.3% YoY
|
| SGA |
21.71M
est: 35.29M (-38.5%)
|
34.62M
est: 43.13M (-19.7%)
|
51.63M
est: 180.47M (-71.4%)
|
66.61M
est: 232.46M (-71.3%)
|
65.88M
est: 254.33M (-74.1%)
|
66.75M
est: 266.96M (-75.0%)
|
95.28M
est: 98.63M (-3.4%)
|
88.38M
est: 101.09M (-12.6%)
|
158.79M
est: 101.16M (+57.0%)
|
104.36M
102.77M – 106.02M
+3.2% YoY
|
108.30M
106.62M – 110.48M
+3.8% YoY
|
111.00M
110.73M – 111.28M
+2.5% YoY
|
116.02M
114.24M – 118.12M
+4.5% YoY
|
| EPS |
1.56
est: 0.44 (+251.3%)
|
1.41
est: 1.44 (-2.1%)
|
1.43
est: 1.69 (-15.2%)
|
1.59
est: 1.82 (-12.5%)
|
3.89
est: 3.91 (-0.6%)
|
2.49
est: 3.64 (-31.6%)
|
1.16
est: 1.54 (-24.6%)
|
2.11
est: 2.04 (+3.7%)
|
2.46
est: 2.25 (+9.5%)
|
2.45
2.30 – 2.60
+9.1% YoY
|
2.66
2.40 – 2.89
+8.6% YoY
|
2.95
2.60 – 3.26
+10.9% YoY
|
3.40
3.33 – 3.48
+15.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi SDAX UCITS ETF Dist C005.DE | 0.95% | 1.69M | 0.70% |
| 2 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.49% | 451.8K | 0.38% |
| 3 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.49% | 451.8K | 0.38% |
| 4 | Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA | 0.41% | 2.93M | 0.40% |
| 5 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.18% | 771.7K | 0.48% |
| 6 | WisdomTree International SmallCap Dividend Fund DLS | 0.18% | 1.83M | 0.58% |
| 7 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.17% | 576.9K | 0.23% |
| 8 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.17% | 576.9K | 0.23% |
| 9 | UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE | 0.08% | 585.9K | 0.33% |
| 10 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.08% | 814.0K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hans-Georg Feldmeier | Chief Executive Officer & Chairman of the Management Board | 1M | — |
| Andreas Eberhorn | Chief Marketing Officer & Member of Management Board | 675.0K | — |
| Christof Dreibholz | Chief Financial Officer, Chief Compliance Officer & Member of Management Board | 674.0K | male |
| Britta Hamberger | Head of Investor Relations & Corporation Communications | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DMP.DE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
